1. Medtech Insight
  2. >>Business

Myriad To Enter Neuroscience Market With $225m Assurex Acquisition

In its bid to develop more targeted diagnostics and build future partnerships with pharma companies, Myriad has signed a $225m deal, plus milestones, to acquire Assurex Health.

Myriad Genetics Inc. has signed a definitive agreement to acquire Assurex Health Inc. for $225m upfront to move into the neuroscience personalized medicine market. The company says it will pay out an additional $185m based on performance-based milestones. If all goes according to plan, the deal is expected to close in the first quarter of 2017.

With the deal, Myriad will gain Assurex's GeneSight, a laboratory-developed genomic test that analyzes the pharmacokinetic and pharmacodynamics effects of 55 antidepressant/antipsychotic/mental health medications drugs based on patients' genetic make-up

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Does Makary’s Reorg Choice Mark FDA Turning Point?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.